Remove tag treatment-access
article thumbnail

STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available

STAT

In the latest bid to widen access to medicines, a nonprofit is sending technology and materials for making expensive CAR-T cell therapies to the Brazilian government and an Indian manufacturer that will, in turn, look to provide the treatments available at a fraction of current prices in the U.S.

130
130
article thumbnail

STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps

STAT

Instead, the lawmakers introduced a watered-down version to require the Prescription Drug Affordability Board to consider different uses of any medicine with a so-called orphan designation, which refers to treatments for rare diseases. Continue to STAT+ to read the full story…

104
104
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies

STAT

In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell disease, the U.S. government on Tuesday announced a long-awaited “access model” designed to blunt the cost that state Medicaid programs would pay for these curative treatments. million and $3.1

127
127
article thumbnail

Free access to Zolgensma curbed, says Novartis

pharmaphorum

Novartis’ programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Pause in UK access.

119
119
article thumbnail

STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more

STAT

In response to concerns over multi-million-dollar price tags for new gene therapies for sickle cell disease, the U.S. government announced a long-awaited “access model” designed to blunt the cost that state Medicaid programs would pay for these curative treatments , STAT says. Two million and $3.1

85
article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the company. million price tag make it is the most expensive treatment ever approved for NHS funding.

97
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 This is not the first treatment to come with a high price tag.

FDA 105